Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Wave Life Sciences Ltd. - Ordinary Shares
(NQ:
WVE
)
15.74
+0.59 (+3.89%)
Streaming Delayed Price
Updated: 9:58 AM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Wave Life Sciences Ltd. - Ordinary Shares
< Previous
1
2
3
4
Next >
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
December 09, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
ENDRA Life Sciences (NASDAQ: NDRA) Advances TAEUS® Liver Imaging, Strengthens Capital Efficiency; WVE, TWG, BDRX, FULC Also Active
December 09, 2025
Via
AB Newswire
Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
December 08, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
December 08, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025
December 07, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update
November 10, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at Upcoming Investor Conferences
November 07, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
November 04, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025
November 04, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
October 29, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
October 29, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences
September 18, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
September 03, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
July 30, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025
July 23, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions
June 20, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference
May 29, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer
May 28, 2025
Dr. Wright brings deep experience across a wide breadth of therapeutic areas and modalities and will guide clinical development of Wave’s robust RNA medicines pipeline
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
May 08, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025
May 01, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531
March 26, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 04, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025
February 25, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity
February 06, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation
January 13, 2025
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
December 23, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
December 16, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at Upcoming Investor Conferences
November 26, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at Jefferies London Healthcare Conference
November 15, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
